Incyte Corporation

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. Our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. The Incyte corporate headquarters is located in Wilmington, Delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders.
Company Growth (employees)
Wilmington, US
Size (employees)
980 (est)
Incyte Corporation was founded in 1991 and is headquartered in Wilmington, US

Incyte Corporation Office Locations

Incyte Corporation has offices in Wilmington, Genève, Geneva, Lausanne and in 7 other locations
Wilmington, US (HQ)
1801 Augustine Rd
Genève, CH
1 Rue Du Pré De La Bichette
Show all (11)

Incyte Corporation Data and Metrics

Incyte Corporation Financial Metrics

Incyte Corporation's revenue was reported to be $1.1 b in FY, 2016 which is a 47% increase from the previous period.

Revenue (FY, 2016)

1.1 b

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

104.2 m

EBIT (FY, 2016)

145 m

Market capitalization (19-Jul-2017)

26.7 b

Closing share price (19-Jul-2017)


Cash (31-Dec-2016)

652.3 m
Incyte Corporation's current market capitalization is $26.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


354.9 m511.5 m753.8 m1.1 b

Revenue growth, %


R&D expense

581.9 m

General and administrative expense

303.3 m

Operating expense total

371 m516.3 m703.1 m960.7 m


(16.1 m)(4.8 m)50.7 m145 m

EBIT margin, %


Interest expense

38.7 m46.8 m45.6 m38.7 m

Interest income

1.3 m3.4 m7.1 m4.4 m

Pre tax profit

(82.8 m)(48.5 m)

Income tax expense

299 k(66 k)1 m3.2 m

Net Income

(83.1 m)(48.5 m)6.5 m104.2 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


471.4 m452.3 m521.4 m652.3 m

Accounts Receivable

35.4 m57.9 m114.5 m148.8 m


9.6 m20.5 m17.8 m4.1 m

Current Assets

555.8 m699.2 m842.4 m994.2 m


26.8 m81.8 m86 m167.7 m


155.6 m

Total Assets

629.6 m830.1 m1 b1.6 b

Accounts Payable

19.1 m24.5 m30.1 m75.6 m

Current Liabilities

108 m221.5 m168 m273.5 m

Total Liabilities

1.2 b

Additional Paid-in Capital

1.5 b1.7 b2 b2.1 b

Retained Earnings

(1.7 b)(1.8 b)(1.8 b)(1.7 b)

Total Equity

(193.1 m)(81.6 m)171.2 m419.5 m

Financial Leverage

-3.3 x-10.2 x5.9 x3.9 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(83.1 m)(48.5 m)6.5 m104.2 m

Depreciation and Amortization

58.4 m

Accounts Receivable

35.6 m(23 m)114 m(23.9 m)


(6.6 m)(4.1 m)17.8 m4 m

Accounts Payable

5.1 m5.4 m30.1 m43.8 m

Cash From Operating Activities

9.2 m26.3 m304.8 m

Capital Expenditures

(4.3 m)(27.9 m)(120.3 m)

Cash From Investing Activities

(37.4 m)(138.4 m)(232.5 m)

Cash From Financing Activities

275.6 m93.1 m58.6 m

Interest Paid

15.6 m10.5 m7.2 m

Income Taxes Paid

927 k

Free Cash Flow

13.4 m54.1 m184.5 m
USDY, 2016


1.1 m

Financial Leverage

3.9 x

Incyte Corporation Market Value History

Incyte Corporation Job Categories

Incyte Corporation Median Salaries

Source: 40 public H-1B filings from Incyte Corporation

Incyte Corporation Online and Social Media Presence

Incyte Corporation News and Updates

Incyte Corporation Company Life and Culture

You may also be interested in